CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant 

Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and remains an advocate for the HIV patient. He formed the Kaposi’s Sarcoma Research & Education Foundation in 1982, which later became the San Francisco AIDS Foundation. On this episode of Cell & Gene: The Podcast, Dr. Conant shares the why behind cell and gene therapy to treat HIV, and he explains Addimmune’s lead asset, AGT103-T, which is designed to provide broad protection using silencing RNA to inhibit binding/entry of the virus, halt replication, and prevent escape.
--
#celltherapy #genetherapy
Subscribe to the podcast!
Apple - podcasts.apple...
Spotify - open.spotify.c...
RU-vid - • Cell & Gene The Podcast